Patents Assigned to Wyeth
  • Patent number: 9688735
    Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: June 27, 2017
    Assignee: Wyeth LLC
    Inventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
  • Patent number: 9675681
    Abstract: A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: June 13, 2017
    Assignee: Wyeth LLC
    Inventors: Yonghui Yuan, Mark Ruppen, Wei-Qiang Sun, Ling Chu, John Simpson, James Patch, Justin Keith Moran, Pamela S. Fink
  • Patent number: 9669084
    Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: June 6, 2017
    Assignee: Wyeth LLC
    Inventors: George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
  • Patent number: 9644025
    Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: May 9, 2017
    Assignees: WYETH LLC, JANSSEN SCIENCES IRELAND UC
    Inventors: Ronald Black, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Jack Steven Jacobsen, Davinder Gill, Lioudmila Tchistiakova, Angela Widom
  • Patent number: 9630946
    Abstract: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: April 25, 2017
    Assignee: WYETH LLC
    Inventors: Quinhong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi
  • Patent number: 9623100
    Abstract: The present invention relates to immunogenic conjugates comprising S. aureus serotype 5 and 8 capsular polysaccharides conjugated to carrier proteins and methods for their preparation and use. Methods for making the immunogenic conjugates of the invention involve covalent conjugation of the capsular polysaccharides with the carrier proteins using conjugation chemistry involving either 1,1-carbonyl-di-1,2,4-triazole (CDT) or 3-(2-pyridyldithio)-propionyl hydrazide (PDPH).
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: April 18, 2017
    Assignee: Wyeth LLC
    Inventors: Stephen John Freese, Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Tracy Dee Scott, Jasdeep Singh Nanra, A. Krishna Prasad, Bruce Arthur Green
  • Patent number: 9623101
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: April 18, 2017
    Assignee: Wyeth Holdings LLC
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Patent number: 9592202
    Abstract: The present invention provides for compositions comprising glucosamine wherein the glucosamine has improved and/or enhanced stability. Additionally, the present invention provides for methods of stabilizing compositions for use in preparing an oral dosage form comprising glucosamine.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: March 14, 2017
    Assignee: WYETH LLC
    Inventors: Scott William Poxon, Denise Lowe Walters
  • Publication number: 20170065567
    Abstract: An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 9, 2017
    Applicant: Wyeth LLC
    Inventors: Jay Dickerson, William Mark, Annabelle Trimmer, David Jaeger, Amanda Alley
  • Patent number: 9586180
    Abstract: The present invention relates to methods of generating highly concentrated protein solutions, e.g., an antibody solution, a therapeutic protein solution, etc. The methods of the invention include membrane evaporation, such as evaporation of protein-free solvent from the protein solution, which concentrates the protein. The methods of the present invention result in protein solution concentrations not previously achievable by conventional ultrafiltration methods, e.g., protein solution concentrations of greater than about 260 grams of protein per liter of solution.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: March 7, 2017
    Assignee: Wyeth LLC
    Inventors: Glen Reed Bolton, Hari Acharya, Austin Wayne Boesch
  • Patent number: 9566186
    Abstract: A portable moist heat delivery system comprising a water vapor generating portion comprising a water vapor source and a heat source; a water vapor-air regulating portion, said water vapor-air regulating portion comprising a water vapor-air mixing layer, and a water vapor-air distribution layer; said water vapor generating portion and said water vapor-air regulating portion being in fluid communication; and said water vapor-air regulating portion having a latent heat delivery surface disposed adjacent said water vapor-air regulating portion which delivers moist heat at a preselected temperature range wherein about 15% to about 95% of the moist heat is latent heat of condensation. Methods include delivering improved pain relief, blood flow, relaxation, and reduced cardiac workload.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: February 14, 2017
    Assignee: Wyeth LLC
    Inventors: Vincent York-Leung Wong, Marina Belkin, Chad Kamil Hickson, Leroy Glenn Owens, Jr.
  • Patent number: 9556240
    Abstract: The present invention relates to stable formulations of Neisseria meningitis rLP2086 Subfamily B Antigens in immunogenic compositions. The present invention also relates to methods of preserving the conformation of Neisseria meningitis rLP2086 Antigens and methods for determining the potency of Neisseria meningitis rLP2086 antigens.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: January 31, 2017
    Assignee: Wyeth LLC
    Inventors: Lakshmi Khandke, Rasappa Arumugham, Bounthon Loun
  • Patent number: 9523092
    Abstract: The present invention provides a polynucleotide vector system used during polypeptide display that can be used to facilitate transfer of pools of polynucleotides encoding antigen binding proteins of interest. The present invention also provides methods that allow seamless conversion of pools of polynucleotides encoding antigen binding proteins using a restriction enzyme digestion and ligation strategy.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: December 20, 2016
    Assignee: Wyeth LLC
    Inventors: Simon Evan Hufton, William James Jonathan Finlay
  • Patent number: 9511063
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: December 6, 2016
    Assignee: WYETH LLC
    Inventor: Charles Michael Zacharchuk
  • Patent number: 9505831
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: November 29, 2016
    Assignee: Wyeth LLC
    Inventors: Jane Aghajanian, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Tejvir S. Khurana, Mary L. Bouxsein
  • Publication number: 20160338946
    Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.
    Type: Application
    Filed: May 19, 2016
    Publication date: November 24, 2016
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christian Ofslager, Mahdi B. Fawzi, Nataliya Bazhina
  • Patent number: 9492445
    Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: November 15, 2016
    Assignee: Wyeth, LLC
    Inventors: Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
  • Publication number: 20160324735
    Abstract: A topical treatment strip comprising a substrate having two surfaces with a topical composition carried thereupon. The treatment strip can be used to treat two surfaces of subject such as both lips simultaneously. Methods include methods of manufacture and methods of use.
    Type: Application
    Filed: June 17, 2016
    Publication date: November 10, 2016
    Applicant: Wyeth LLC
    Inventor: Jian-Hwa Guo
  • Publication number: 20160326496
    Abstract: Isolated and enriched tumor-initiating cell populations, methods for preparing the same, and uses thereof.
    Type: Application
    Filed: April 14, 2016
    Publication date: November 10, 2016
    Applicant: WYETH LLC
    Inventors: Marc Isaac Damelin, Kenneth G. Geles, Jonathon P. Golas, Erwin Boghaert, Bin-Bing S. Zhou
  • Patent number: RE46376
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 25, 2017
    Assignee: Wyeth LLC
    Inventors: Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Michael James Flint